Eli Lilly and Company  
Attention: Beth Weinberg, R.Ph.  
Manager, U.S. Regulatory Affairs  
Lilly Corporate Center  
Indianapolis, IN 46285

Dear Ms. Weinberg:  

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received November 20, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for: Humulin R (insulin human injection, USP [rDNA origin]), 100 IU/mL, Humulin N NPH (human insulin [rDNA origin] isophane suspension), 100 IU/mL, and Humulin Mix 70/30 (70% human insulin isophane suspension/30% human insulin injection [rDNA origin]) 100 IU/mL.

These “Prior Approval” supplemental new drug applications provide for the addition of packaging that includes the “ReliOn” logo on the carton and container labeling and also updates the ‘Vials manufactured by’ area of the ADDITONAL INFORMATION section of the Patient Package Insert (PPI) labeling to indicate that the products are packaged for Walmart stores.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm), that is identical to the enclosed labeling text for the patient package insert submitted November 20, 2009, and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf).

The SPL will be accessible from publicly available labeling repositories.
Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

**CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels submitted on November 20, 2009, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)”. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 018780/S-120, NDA 018781/S-114, and NDA 019717/S-094.” Approval of this submission by FDA is not required before the labeling is used.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

As required under 21 CFR 314.81(b)(3)(i), you must submit your updated final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA-2253, directly to the above address. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
Please submit one market package of the drug product when it is available.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch
Food and Drug Administration
Suite 12B-05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rachel Hartford, Regulatory Project Manager, at (301) 796-0331.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Humulin R Vial – PPI, carton, container
Humulin N Vial – PPI, carton, container
Humulin 70/30 Vial – PPI, carton, container
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-19717</td>
<td>SUPPL-94</td>
<td>ELI LILLY AND CO</td>
<td>HUMULIN 70/30</td>
</tr>
<tr>
<td>NDA-18781</td>
<td>SUPPL-114</td>
<td>ELI LILLY AND CO</td>
<td>HUMULIN N</td>
</tr>
<tr>
<td>NDA-18780</td>
<td>SUPPL-128</td>
<td>ELI LILLY AND CO</td>
<td>HUMULIN R</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY H PARKS
06/10/2010